{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:50:03Z","timestamp":1792601403467,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Previous meta-analyses have found that systemic medications may modulate dementia risk. We aimed to provide an overview of this evidence to guide clinical practice and future research.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted an umbrella review of meta-analyses (PROSPERO CRD42021226307), searching databases from inception to 15th April 2024. Only peer-reviewed meta-analyses examining dementia risk and systemic medications in humans were included. Two authors independently screened studies for inclusion, extracted study data and assessed quality of meta-analyses using the AMSTAR-2 tool. Three authors independently rated the certainty of evidence for each drug using the GRADE framework.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>68 meta-analyses were included, across 11 drug categories. Across meta-analyses, available data were primarily observational. Confounding by indication and potential reverse causality were important limitations. Randomised-controlled data were rare but supported an association between treatment of hypertension and reduced dementia incidence. Overall, we found moderate certainty evidence of reduced risk of dementia associated with anti-hypertensives, statins, sodium-glucose transport protein 2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), and moderate certainty of increased risk with anticholinergics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Currently, there is insufficient evidence to advise repurposing any systemic drugs with the primary aim of reducing dementia risk. On the basis of our findings, we recommend proactive treatment of hypertension to reduce risk of all-cause dementia. Our findings did not find a difference between antihypertensive drug classes, but dementia risk was associated with blood pressure reading. In addition, we advise avoidance of anticholinergic drugs in cognitive impairment, with assessment of anticholinergic burden and consideration of alternatives during routine clinical contacts.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1038\/s41380-025-03129-3","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T10:00:49Z","timestamp":1753351249000},"page":"5578-5599","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic medications and dementia risk: a systematic umbrella review"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6900-2678","authenticated-orcid":false,"given":"Clara","family":"Belessiotis-Richards","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Feng Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivangi","family":"Talwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Eskinazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqianglong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar A.","family":"Letrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Morelli-Batters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9620-0290","authenticated-orcid":false,"given":"Andrea","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talen","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8635-9521","authenticated-orcid":false,"given":"Naaheed","family":"Mukadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"3129_CR1","unstructured":"Prince M, Wimo, A, Guerchet, M, Ali, G, Wu, Y, Prina, M, et al. The World Alzheimer Report 2015: the global impact of dementia: global observatory for ageing and dementia care. Published by Alzheimer\u2019s Disease International (ADI), London. 2015. Accessed via: https:\/\/www.alzint.org\/u\/WorldAlzheimerReport2015.pdf."},{"key":"3129_CR2","doi-asserted-by":"publisher","first-page":"949","DOI":"10.2147\/CLEP.S152647","volume":"10","author":"TM Pham","year":"2018","unstructured":"Pham TM, Petersen I, Walters K, Raine R, Manthorpe J, Mukadam N, et al. Trends in dementia diagnosis rates in UK ethnic groups: analysis of UK primary care data. Clin Epidemiol. 2018;10:949\u201360.","journal-title":"Clin Epidemiol"},{"key":"3129_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1504327","volume":"374","author":"CL Satizabal","year":"2016","unstructured":"Satizabal CL, Beiser AS, Chouraki V, Ch\u00eane G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the framingham heart study. N Engl J Med. 2016;374:523\u201332.","journal-title":"N Engl J Med"},{"key":"3129_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selb\u00e6k G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572\u2013628.","journal-title":"Lancet"},{"key":"3129_CR5","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jalz.2015.05.016","volume":"11","author":"M Baumgart","year":"2015","unstructured":"Baumgart M, Snyder HM, Carrillo MC, Fazio S, Kim H, Johns H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: a population-based perspective. Alzheimers Dement. 2015;11:718\u201326.","journal-title":"Alzheimers Dement"},{"key":"3129_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002853","volume":"16","author":"DM Lipnicki","year":"2019","unstructured":"Lipnicki DM, Makkar SR, Crawford JD, Thalamuthu A, Kochan NA, Lima-Costa MF, et al. Determinants of cognitive performance and decline in 20 diverse ethno-regional groups: a COSMIC collaboration cohort study. PLoS Med. 2019;16:e1002853.","journal-title":"PLoS Med"},{"key":"3129_CR7","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788\u201394.","journal-title":"Lancet Neurol"},{"key":"3129_CR8","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S1474-4422(11)70072-2","volume":"10","author":"DE Barnes","year":"2011","unstructured":"Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer\u2019s disease prevalence. Lancet Neurol. 2011;10:819\u201328.","journal-title":"Lancet Neurol"},{"key":"3129_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396:413\u201346.","journal-title":"Lancet"},{"key":"3129_CR10","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","volume":"162","author":"F Forette","year":"2002","unstructured":"Forette F, Seux M-L, Staessen JA, Thijs L, Babarskiene M-R, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046\u201352.","journal-title":"Arch Intern Med"},{"key":"3129_CR11","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard CH, Friedrich S, Hansen CT, Gerds T, Ballard C, M\u00f8ller DV, et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimers Dement. 2022;8:e12268.","journal-title":"Alzheimers Dement"},{"key":"3129_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1136\/ebmental-2018-300014","volume":"21","author":"P Fusar-Poli","year":"2018","unstructured":"Fusar-Poli P, Radua J. Ten simple rules for conducting umbrella reviews. Evid Based Ment Health. 2018;21:95\u2013100.","journal-title":"Evid Based Ment Health"},{"key":"3129_CR13","unstructured":"Ying Feng Yap NM, Hayes J. Systemic medications and dementia risk: umbrella review of systematic reviews and meta-analyses. 2021. https:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?RecordID=226307."},{"key":"3129_CR14","doi-asserted-by":"publisher","first-page":"e070849","DOI":"10.1136\/bmj-2022-070849","volume":"378","author":"M Gates","year":"2022","unstructured":"Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022;378:e070849.","journal-title":"BMJ"},{"key":"3129_CR15","unstructured":"Organisation WH. Anatomical therapeutic chemical (ATC) classification. 2023. https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification."},{"key":"3129_CR16","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"3129_CR17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jclinepi.2013.11.007","volume":"67","author":"D Pieper","year":"2014","unstructured":"Pieper D, Antoine SL, Mathes T, Neugebauer EA, Eikermann M. Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014;67:368\u201375.","journal-title":"J Clin Epidemiol"},{"key":"3129_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/jrsm.1390","volume":"11","author":"EA Hennessy","year":"2020","unstructured":"Hennessy EA, Johnson BT. Examining overlap of included studies in meta-reviews: guidance for using the corrected covered area index. Res Synth Methods. 2020;11:134\u201345.","journal-title":"Res Synth Methods"},{"key":"3129_CR19","unstructured":"Pollock M, Fernandes R, Becker LA, Pieper D, Hartling L. Chapter V: overviews of reviews. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 63. Cochrane; 2022. Available from www.cochrane.org\/handbook."},{"key":"3129_CR20","unstructured":"Cochrane. Chapter 14: completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. editors. Cochrane handbook for systematic reviews of interventions version 65. Cochrane; 2024. Available from www.cochrane.org\/handbook"},{"key":"3129_CR21","doi-asserted-by":"publisher","first-page":"715","DOI":"10.14283\/jpad.2022.77","volume":"9","author":"M Adesuyan","year":"2022","unstructured":"Adesuyan M, Jani YH, Alsugeir D, Cheung ECL, Chui CSL, Howard R, et al. Antihypertensive agents and incident alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. J Prev Alzheimers Dis. 2022;9:715\u201324.","journal-title":"J Prev Alzheimers Dis"},{"key":"3129_CR22","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1093\/eurheartj\/ehac584","volume":"43","author":"R Peters","year":"2022","unstructured":"Peters R, Xu Y, Fitzgerald O, Aung HL, Beckett N, Bulpitt C, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43:4980\u201390.","journal-title":"Eur Heart J"},{"key":"3129_CR23","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1001\/jama.2020.4249","volume":"323","author":"D Hughes","year":"2020","unstructured":"Hughes D, Judge C, Murphy R, Loughlin E, Costello M, Whiteley W, et al. Association of blood pressure lowering with incident dementia or cognitive impairment: a systematic review and meta-analysis. JAMA. 2020;323:1934\u201344.","journal-title":"JAMA"},{"key":"3129_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1161\/HYPERTENSIONAHA.120.14993","volume":"76","author":"YN Ou","year":"2020","unstructured":"Ou YN, Tan CC, Shen XN, Xu W, Hou XH, Dong Q, et al. Blood pressure and risks of cognitive impairment and dementia: a systematic review and meta-analysis of 209 prospective studies. Hypertension. 2020;76:217\u201325.","journal-title":"Hypertension"},{"key":"3129_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4368474","volume":"2017","author":"G Xu","year":"2017","unstructured":"Xu G, Bai F, Lin X, Wang Q, Wu Q, Sun S, et al. Association between antihypertensive drug use and the incidence of cognitive decline and dementia: a meta-analysis of prospective cohort studies. Biomed Res Int. 2017;2017:4368474.","journal-title":"Biomed Res Int"},{"key":"3129_CR26","volume":"5","author":"EL Cunningham","year":"2021","unstructured":"Cunningham EL, Todd SA, Passmore P, Bullock R, McGuinness B. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database Syst Rev. 2021;5:CD004034.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/ijcp.12626","volume":"69","author":"R Ye","year":"2015","unstructured":"Ye R, Hu Y, Yao A, Yang Y, Shi Y, Jiang Y, et al. Impact of renin-angiotensin system-targeting antihypertensive drugs on treatment of Alzheimer\u2019s disease: a meta-analysis. Int J Clin Pract. 2015;69:674\u201381.","journal-title":"Int J Clin Pract"},{"key":"3129_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.neulet.2018.02.027","volume":"671","author":"S Hussain","year":"2018","unstructured":"Hussain S, Singh A, Rahman SO, Habib A, Najmi AK. Calcium channel blocker use reduces incident dementia risk in elderly hypertensive patients: a meta-analysis of prospective studies. Neurosci Lett. 2018;671:120\u20137.","journal-title":"Neurosci Lett"},{"key":"3129_CR29","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1097\/HJH.0000000000001829","volume":"36","author":"T van Middelaar","year":"2018","unstructured":"van Middelaar T, van Vught LA, van Gool WA, Simons EMF, van den Born BH, Moll van Charante EP, et al. Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis. J Hypertens. 2018;36:1780\u20137.","journal-title":"J Hypertens"},{"key":"3129_CR30","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1111\/j.1742-1241.2011.02810.x","volume":"65","author":"H Chang-Quan","year":"2011","unstructured":"Chang-Quan H, Hui W, Chao-Min W, Zheng-Rong W, Jun-Wen G, Yong-Hong L, et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int J Clin Pract. 2011;65:1295\u2013305.","journal-title":"Int J Clin Pract"},{"key":"3129_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","volume":"19","author":"J Ding","year":"2020","unstructured":"Ding J, Davis-Plourde KL, Sedaghat S, Tully PJ, Wang W, Phillips C, et al. Antihypertensive medications and risk for incident dementia and Alzheimer\u2019s disease: a meta-analysis of individual participant data from prospective cohort studies. Lancet Neurol. 2020;19:61\u201370.","journal-title":"Lancet Neurol"},{"key":"3129_CR32","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2217\/fca.15.90","volume":"12","author":"C Parsons","year":"2016","unstructured":"Parsons C, Murad MH, Andersen S, Mookadam F, Labonte H. The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis. Future Cardiol. 2016;12:237\u201348.","journal-title":"Future Cardiol"},{"key":"3129_CR33","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1097\/HJH.0b013e3283603f53","volume":"31","author":"N Levi Marpillat","year":"2013","unstructured":"Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens. 2013;31:1073\u201382.","journal-title":"J Hypertens"},{"key":"3129_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1136\/jnnp.2007.118505","volume":"79","author":"B McGuinness","year":"2008","unstructured":"McGuinness B, Todd S, Passmore AP, Bullock R. Systematic review: blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. J Neurol Neurosurg Psychiatry. 2008;79:4\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3129_CR35","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1097\/HJH.0000000000000273","volume":"32","author":"R Peters","year":"2014","unstructured":"Peters R, Booth A, Peters J. A systematic review of calcium channel blocker use and cognitive decline\/dementia in the elderly. J Hypertens. 2014;32:1945\u201357.","journal-title":"J Hypertens"},{"key":"3129_CR36","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1212\/WNL.0000000000008732","volume":"94","author":"R Peters","year":"2020","unstructured":"Peters R, Yasar S, Anderson CS, Andrews S, Antikainen R, Arima H, et al. Investigation of antihypertensive class, dementia, and cognitive decline: a meta-analysis. Neurology. 2020;94:e267\u2013e81.","journal-title":"Neurology"},{"key":"3129_CR37","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.neulet.2016.05.003","volume":"624","author":"S Zhuang","year":"2016","unstructured":"Zhuang S, Wang HF, Li J, Wang HY, Wang X, Xing CM. Renin-angiotensin system blockade use and risks of cognitive decline and dementia: a meta-analysis. Neurosci Lett. 2016;624:53\u201361.","journal-title":"Neurosci Lett"},{"key":"3129_CR38","doi-asserted-by":"publisher","first-page":"e2333353","DOI":"10.1001\/jamanetworkopen.2023.33353","volume":"6","author":"MJ Lennon","year":"2023","unstructured":"Lennon MJ, Lam BCP, Lipnicki DM, Crawford JD, Peters R, Schutte AE, et al. Use of antihypertensives, blood pressure, and estimated risk of dementia in late life: an individual participant data meta-analysis. JAMA Network Open. 2023;6:e2333353.","journal-title":"JAMA Network Open"},{"key":"3129_CR39","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"3129_CR40","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurjpc\/zwab208","volume":"29","author":"E Olmastroni","year":"2022","unstructured":"Olmastroni E, Molari G, De Beni N, Colpani O, Galimberti F, Gazzotti M, et al. Statin use and risk of dementia or Alzheimer\u2019s disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29:804\u201314.","journal-title":"Eur J Prev Cardiol"},{"key":"3129_CR41","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000503105","volume":"54","author":"TN Poly","year":"2020","unstructured":"Poly TN, Islam MM, Walther BA, Yang HC, Wu CC, Lin MC, et al. Association between use of statin and risk of dementia: a meta-analysis of observational studies. Neuroepidemiology. 2020;54:214\u201326.","journal-title":"Neuroepidemiology"},{"key":"3129_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-24248-8","volume":"8","author":"CS Chu","year":"2018","unstructured":"Chu CS, Tseng PT, Stubbs B, Chen TY, Tang CH, Li DJ, et al. Use of statins and the risk of dementia and mild cognitive impairment: a systematic review and meta-analysis. Sci Rep. 2018;8:5804.","journal-title":"Sci Rep"},{"key":"3129_CR43","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ggi.12044","volume":"13","author":"Y Song","year":"2013","unstructured":"Song Y, Nie H, Xu Y, Zhang L, Wu Y. Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int. 2013;13:817\u201324.","journal-title":"Geriatr Gerontol Int"},{"key":"3129_CR44","doi-asserted-by":"publisher","first-page":"e11304","DOI":"10.1097\/MD.0000000000011304","volume":"97","author":"X Zhang","year":"2018","unstructured":"Zhang X, Wen J, Zhang Z. Statins use and risk of dementia: a dose-response meta analysis. Medicine. 2018;97:e11304.","journal-title":"Medicine"},{"key":"3129_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1002\/pds.3381","volume":"22","author":"WB Wong","year":"2013","unstructured":"Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer\u2019s disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22:345\u201358.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3129_CR46","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000099037","volume":"23","author":"B Zhou","year":"2007","unstructured":"Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer\u2019s disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 2007;23:194\u2013201.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3129_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"key":"3129_CR48","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00228-019-02753-7","volume":"76","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Liang M, Sun C, Song EJ, Cheng C, Shi T, et al. Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies. Eur J Clin Pharmacol. 2020;76:139\u201347.","journal-title":"Eur J Clin Pharmacol"},{"key":"3129_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/jgh.14789","volume":"35","author":"S Hussain","year":"2020","unstructured":"Hussain S, Singh A, Zameer S, Jamali MC, Baxi H, Rahman SO, et al. No association between proton pump inhibitor use and risk of dementia: evidence from a meta-analysis. J Gastroenterol Hepatol. 2020;35:19\u201328.","journal-title":"J Gastroenterol Hepatol"},{"key":"3129_CR50","doi-asserted-by":"publisher","first-page":"135","DOI":"10.7704\/kjhugr.2020.0057","volume":"21","author":"K-T Yoon","year":"2021","unstructured":"Yoon K-T, Bang CS, Kim JS. Proton-pump inhibitors and the risk of dementia: a systematic review and meta-analysis. Korean J Helicobacter Up Gastrointest Res. 2021;21:135\u201343.","journal-title":"Korean J Helicobacter Up Gastrointest Res"},{"key":"3129_CR51","doi-asserted-by":"publisher","first-page":"doaa041","DOI":"10.1093\/dote\/doaa041","volume":"33","author":"M Desai","year":"2020","unstructured":"Desai M, Nutalapati V, Srinivasan S, Fathallah J, Dasari C, Chandrasekhar VT, et al. Proton pump inhibitors do not increase the risk of dementia: a systematic review and meta-analysis of prospective studies. Dis Esophagus. 2020;33:doaa041.","journal-title":"Dis Esophagus"},{"key":"3129_CR52","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/EDE.0000000000000326","volume":"26","author":"SA Virk","year":"2015","unstructured":"Virk SA, Eslick GD. Brief report: meta-analysis of antacid use and Alzheimer\u2019s disease: implications for the aluminum hypothesis. Epidemiology. 2015;26:769\u201373.","journal-title":"Epidemiology"},{"key":"3129_CR53","doi-asserted-by":"publisher","first-page":"e14422","DOI":"10.1097\/MD.0000000000014422","volume":"98","author":"M Li","year":"2019","unstructured":"Li M, Luo Z, Yu S, Tang Z. Proton pump inhibitor use and risk of dementia: systematic review and meta-analysis. Medicine. 2019;98:e14422.","journal-title":"Medicine"},{"key":"3129_CR54","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1053\/j.gastro.2019.05.056","volume":"157","author":"P Moayyedi","year":"2019","unstructured":"Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019;157:682\u201391.e2.","journal-title":"Gastroenterology"},{"key":"3129_CR55","doi-asserted-by":"publisher","first-page":"e000563","DOI":"10.1136\/bmjdrc-2018-000563","volume":"6","author":"JM McMillan","year":"2018","unstructured":"McMillan JM, Mele BS, Hogan DB, Leung AA. Impact of pharmacological treatment of diabetes mellitus on dementia risk: systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2018;6:e000563.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3129_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154265","volume":"109","author":"JB Zhou","year":"2020","unstructured":"Zhou JB, Tang X, Han M, Yang J, Sim\u00f3 R. Impact of antidiabetic agents on dementia risk: a Bayesian network meta-analysis. Metabolism. 2020;109:154265.","journal-title":"Metabolism"},{"key":"3129_CR57","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000445941","volume":"41","author":"F Ye","year":"2016","unstructured":"Ye F, Luo YJ, Xiao J, Yu NW, Yi G. Impact of insulin sensitizers on the incidence of dementia: a meta-analysis. Dement Geriatr Cogn Disord. 2016;41:251\u201360.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"3129_CR58","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3233\/JAD-180263","volume":"65","author":"JM Campbell","year":"2018","unstructured":"Campbell JM, Stephenson MD, de Courten B, Chapman I, Bellman SM, Aromataris E. Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and meta-analysis. J Alzheimers Dis. 2018;65:1225\u201336.","journal-title":"J Alzheimers Dis"},{"key":"3129_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3673","volume":"39","author":"S Tian","year":"2023","unstructured":"Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, et al. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev. 2023;39:e3673.","journal-title":"Diabetes Metab Res Rev"},{"key":"3129_CR60","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/jgs.18306","volume":"71","author":"H Tang","year":"2023","unstructured":"Tang H, Shao H, Shaaban CE, Yang K, Brown J, Anton S, et al. Newer glucose-lowering drugs and risk of dementia: a systematic review and meta-analysis of observational studies. J Am Geriatr Soc. 2023;71:2096\u2013106.","journal-title":"J Am Geriatr Soc"},{"key":"3129_CR61","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/dom.15331","volume":"26","author":"A Kuate Defo","year":"2024","unstructured":"Kuate Defo A, Bakula V, Pisaturo A, Labos C, Wing SS, Daskalopoulou SS. Diabetes, antidiabetic medications and risk of dementia: a systematic umbrella review and meta-analysis. Diabetes Obes Metab. 2024;26:441\u201362.","journal-title":"Diabetes Obes Metab"},{"key":"3129_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2018.00083","volume":"10","author":"C Zhang","year":"2018","unstructured":"Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID exposure and risk of Alzheimer\u2019s disease: an updated meta-analysis from cohort studies. Front Aging Neurosci. 2018;10:83.","journal-title":"Front Aging Neurosci"},{"key":"3129_CR63","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/bmj.327.7407.128","volume":"327","author":"M Etminan","year":"2003","unstructured":"Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer\u2019s disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.","journal-title":"BMJ"},{"key":"3129_CR64","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1159\/000078501","volume":"23","author":"CA Szekely","year":"2004","unstructured":"Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, et al. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer\u2019s disease: a systematic review. Neuroepidemiology. 2004;23:159\u201369.","journal-title":"Neuroepidemiology"},{"key":"3129_CR65","first-page":"10197","volume":"8","author":"SL Ji","year":"2019","unstructured":"Ji SL, Zhao X-X, Fu T, Liu Y-L, Wang C. The relationship between nonsteroidal anti-inflammatory drug use and the risk of Alzheimer\u2019s disease: an updated meta-analysis of cohort studies. Int J Clin Exp Med. 2019;8:10197\u2013206.","journal-title":"Int J Clin Exp Med"},{"key":"3129_CR66","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1093\/aje\/kwi029","volume":"161","author":"AJ de Craen","year":"2005","unstructured":"de Craen AJ, Gussekloo J, Vrijsen B, Westendorp RG. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol. 2005;161:114\u201320.","journal-title":"Am J Epidemiol"},{"key":"3129_CR67","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1111\/jgs.14883","volume":"65","author":"N Veronese","year":"2017","unstructured":"Veronese N, Stubbs B, Maggi S, Thompson T, Schofield P, Muller C, et al. Low-dose aspirin use and cognitive function in older age: a systematic review and meta-analysis. J Am Geriatr Soc. 2017;65:1763\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"3129_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/epirev\/mxt008","volume":"36","author":"J O\u2019Brien","year":"2014","unstructured":"O\u2019Brien J, Jackson JW, Grodstein F, Blacker D, Weuve J. Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer\u2019s disease. Epidemiol Rev. 2014;36:83\u2013103.","journal-title":"Epidemiol Rev"},{"key":"3129_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104693","volume":"155","author":"M Wu","year":"2020","unstructured":"Wu M, Li M, Yuan J, Liang S, Chen Z, Ye M, et al. Postmenopausal hormone therapy and Alzheimer\u2019s disease, dementia, and Parkinson\u2019s disease: a systematic review and time-response meta-analysis. Pharmacol Res. 2020;155:104693.","journal-title":"Pharmacol Res"},{"key":"3129_CR70","volume-title":"U.S. Preventive services task force evidence syntheses, formerly systematic evidence reviews. Hormone replacement therapy and cognition","author":"E Leblanc","year":"2002","unstructured":"Leblanc E, Chan B, Nelson HD. U.S. Preventive services task force evidence syntheses, formerly systematic evidence reviews. Hormone replacement therapy and cognition. Rockville (MD): Agency for Healthcare Research and Quality (US); 2002."},{"key":"3129_CR71","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1001\/jama.279.9.688","volume":"279","author":"K Yaffe","year":"1998","unstructured":"Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688\u201395.","journal-title":"JAMA"},{"key":"3129_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1260427","volume":"15","author":"M Nerattini","year":"2023","unstructured":"Nerattini M, Jett S, Andy C, Carlton C, Zarate C, Boneu C, et al. Systematic review and meta-analysis of the effects of menopause hormone therapy on risk of Alzheimer\u2019s disease and dementia. Front Aging Neurosci. 2023;15:1260427.","journal-title":"Front Aging Neurosci"},{"key":"3129_CR73","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","volume":"291","author":"SA Shumaker","year":"2004","unstructured":"Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women\u2019s Health Initiative Memory Study. JAMA. 2004;291:2947\u201358.","journal-title":"JAMA"},{"key":"3129_CR74","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.2337\/dc15-1385","volume":"38","author":"MA Espeland","year":"2015","unstructured":"Espeland MA, Brinton RD, Hugenschmidt C, Manson JE, Craft S, Yaffe K, et al. Impact of type 2 diabetes and postmenopausal hormone therapy on incidence of cognitive impairment in older women. Diabetes Care. 2015;38:2316\u201324.","journal-title":"Diabetes Care"},{"key":"3129_CR75","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3233\/JAD-220436","volume":"89","author":"DD Zhang","year":"2022","unstructured":"Zhang DD, Ou YN, Fu Y, Wang ZB, Huang LY, Tan L, et al. Risk of dementia in cancer survivors: a meta-analysis of population-based cohort studies. J Alzheimers Dis. 2022;89:367\u201380.","journal-title":"J Alzheimers Dis"},{"key":"3129_CR76","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/JU.0000000000001341","volume":"205","author":"R Sari Motlagh","year":"2021","unstructured":"Sari Motlagh R, Quhal F, Mori K, Miura N, Aydh A, Laukhtina E, et al. The risk of new onset dementia and\/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. J Urol. 2021;205:60\u20137.","journal-title":"J Urol"},{"key":"3129_CR77","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41391-020-00267-3","volume":"24","author":"H Cui","year":"2021","unstructured":"Cui H, Wang Y, Li F, He G, Jiang Z, Gang X, et al. Quantifying observational evidence for risk of dementia following androgen deprivation therapy for prostate cancer: an updated systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2021;24:15\u201323.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"3129_CR78","doi-asserted-by":"publisher","first-page":"73087","DOI":"10.18632\/oncotarget.20391","volume":"8","author":"JH Kim","year":"2017","unstructured":"Kim JH, Lee B, Han DH, Chung KJ, Jeong IG, Chung BI. Discrepancies on the association between androgen deprivation therapy for prostate cancer and subsequent dementia: meta-analysis and meta-regression. Oncotarget. 2017;8:73087\u201397.","journal-title":"Oncotarget"},{"key":"3129_CR79","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1111\/bcp.15113","volume":"88","author":"A AlDawsari","year":"2022","unstructured":"AlDawsari A, Bushell TJ, Abutheraa N, Sakata S, Al Hussain S, Kurdi A. Use of sedative-hypnotic medications and risk of dementia: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88:1567\u201389.","journal-title":"Br J Clin Pharmacol"},{"key":"3129_CR80","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/phar.2170","volume":"38","author":"RC Lucchetta","year":"2018","unstructured":"Lucchetta RC, da Mata BPM, Mastroianni PC. Association between development of dementia and use of benzodiazepines: a systematic review and meta-analysis. Pharmacotherapy. 2018;38:1010\u201320.","journal-title":"Pharmacotherapy"},{"key":"3129_CR81","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000454881","volume":"47","author":"MM Islam","year":"2016","unstructured":"Islam MM, Iqbal U, Walther B, Atique S, Dubey NK, Nguyen PA, et al. Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis. Neuroepidemiology. 2016;47:181\u201391.","journal-title":"Neuroepidemiology"},{"key":"3129_CR82","doi-asserted-by":"publisher","first-page":"6342","DOI":"10.3390\/jcm12196342","volume":"12","author":"GH Wang","year":"2023","unstructured":"Wang GH, Li P, Wang Y, Guo J, Wilson DL, Lo-Ciganic WH. Association between antidepressants and dementia risk in older adults with depression: a systematic review and meta-analysis. J Clin Med. 2023;12:6342.","journal-title":"J Clin Med"},{"key":"3129_CR83","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/acps.13153","volume":"141","author":"J Velosa","year":"2020","unstructured":"Velosa J, Delgado A, Finger E, Berk M, Kapczinski F, de Azevedo Cardoso T. Risk of dementia in bipolar disorder and the interplay of lithium: a systematic review and meta-analyses. Acta Psychiatr Scand. 2020;141:510\u201321.","journal-title":"Acta Psychiatr Scand"},{"key":"3129_CR84","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/nau.24536","volume":"40","author":"RR Dmochowski","year":"2021","unstructured":"Dmochowski RR, Thai S, Iglay K, Enemchukwu E, Tee S, Varano S, et al. Increased risk of incident dementia following use of anticholinergic agents: a systematic literature review and meta-analysis. Neurourol Urodyn. 2021;40:28\u201337.","journal-title":"Neurourol Urodyn"},{"key":"3129_CR85","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ageing\/afaa090","volume":"49","author":"NT Pieper","year":"2020","unstructured":"Pieper NT, Grossi CM, Chan WY, Loke YK, Savva GM, Haroulis C, et al. Anticholinergic drugs and incident dementia, mild cognitive impairment and cognitive decline: a meta-analysis. Age Ageing. 2020;49:939\u201347.","journal-title":"Age Ageing"},{"key":"3129_CR86","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","volume":"127","author":"YB Zheng","year":"2021","unstructured":"Zheng YB, Shi L, Zhu XM, Bao YP, Bai LJ, Li JQ, et al. Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;127:296\u2013306.","journal-title":"Neurosci Biobehav Rev"},{"key":"3129_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.955878","volume":"14","author":"R Zhao","year":"2022","unstructured":"Zhao R, Han X, Zhang H, Liu J, Zhang M, Zhao W, et al. Association of vitamin E intake in diet and supplements with risk of dementia: a meta-analysis. Front Aging Neurosci. 2022;14:955878.","journal-title":"Front Aging Neurosci"},{"key":"3129_CR88","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/1028415X.2019.1585506","volume":"24","author":"W Wang","year":"2021","unstructured":"Wang W, Li J, Zhang H, Wang X, Zhang X. Effects of vitamin E supplementation on the risk and progression of AD: a systematic review and meta-analysis. Nutr Neurosci. 2021;24:13\u201322.","journal-title":"Nutr Neurosci"},{"key":"3129_CR89","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s41999-022-00720-7","volume":"14","author":"F Zhou","year":"2023","unstructured":"Zhou F, Xie X, Zhang H, Liu T. Effect of antioxidant intake patterns on risks of dementia and cognitive decline. Eur Geriatr Med. 2023;14:9\u201317.","journal-title":"Eur Geriatr Med"},{"key":"3129_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2018.10.025","volume":"96","author":"P Mongkhon","year":"2019","unstructured":"Mongkhon P, Naser AY, Fanning L, Tse G, Lau WCY, Wong ICK, et al. Oral anticoagulants and risk of dementia: a systematic review and meta-analysis of observational studies and randomized controlled trials. Neurosci Biobehav Rev. 2019;96:1\u20139.","journal-title":"Neurosci Biobehav Rev"},{"key":"3129_CR91","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/ageing\/afw104","volume":"45","author":"P Moffitt","year":"2016","unstructured":"Moffitt P, Lane DA, Park H, O\u2019Connell J, Quinn TJ. Thromboprophylaxis in atrial fibrillation and association with cognitive decline: systematic review. Age Ageing. 2016;45:767\u201375.","journal-title":"Age Ageing"},{"key":"3129_CR92","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1161\/STROKEAHA.113.004009","volume":"45","author":"N Mavaddat","year":"2014","unstructured":"Mavaddat N, Roalfe A, Fletcher K, Lip GY, Hobbs FD, Fitzmaurice D, et al. Warfarin versus aspirin for prevention of cognitive decline in atrial fibrillation: randomized controlled trial (Birmingham Atrial Fibrillation Treatment of the Aged Study). Stroke. 2014;45:1381\u20136.","journal-title":"Stroke"},{"key":"3129_CR93","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1017\/S1041610211002778","volume":"24","author":"JS Goveas","year":"2012","unstructured":"Goveas JS, Hogan PE, Kotchen JM, Smoller JW, Denburg NL, Manson JE, et al. Depressive symptoms, antidepressant use, and future cognitive health in postmenopausal women: the women\u2019s health initiative memory study. Int Psychogeriatr. 2012;24:1252\u201364.","journal-title":"Int Psychogeriatr"},{"key":"3129_CR94","first-page":"Cd003160","volume":"2016","author":"B McGuinness","year":"2016","unstructured":"McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;2016:Cd003160.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR95","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","volume":"77","author":"M Sano","year":"2011","unstructured":"Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology. 2011;77:556\u201363.","journal-title":"Neurology"},{"key":"3129_CR96","first-page":"CD012269","volume":"7","author":"J Kwan","year":"2022","unstructured":"Kwan J, Hafdi M, Chiang LW, Myint PK, Wong LS, Quinn TJ. Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia. Cochrane Database Syst Rev. 2022;7:CD012269.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR97","first-page":"CD011459","volume":"4","author":"F Jordan","year":"2020","unstructured":"Jordan F, Quinn TJ, McGuinness B, Passmore P, Kelly JP, Tudur Smith C, et al. Aspirin and other non\u2010steroidal anti-inflammatory drugs for the prevention of dementia. Cochrane Database Syst Rev. 2020;4:CD011459.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR98","first-page":"CD002854","volume":"4","author":"N Farina","year":"2017","unstructured":"Farina N, Llewellyn D, Isaac M, Tabet N. Vitamin E for Alzheimer\u2019s dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2017;4:CD002854.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR99","first-page":"CD011906","volume":"12","author":"AWS Rutjes","year":"2018","unstructured":"Rutjes AWS, Denton DA, Di Nisio M, Chong LY, Abraham RP, Al-Assaf AS, et al. Vitamin and mineral supplementation for maintaining cognitive function in cognitively healthy people in mid and late life. Cochrane Database Syst Rev. 2018;12:CD011906.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR100","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1371\/journal.pctr.0010033","volume":"1","author":"ADAPT Research Group","year":"2006","unstructured":"ADAPT Research Group. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials. 2006;1:e33.","journal-title":"PLoS Clin Trials"},{"key":"3129_CR101","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","volume":"30","author":"LJ Thal","year":"2005","unstructured":"Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology. 2005;30:1204\u201315.","journal-title":"Neuropsychopharmacology"},{"key":"3129_CR102","first-page":"CD003804","volume":"6","author":"A Areosa Sastre","year":"2017","unstructured":"Areosa Sastre A, Vernooij RWM, Gonz\u00e1lez-Cola\u00e7o Harmand M, Mart\u00ednez G. Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2017;6:CD003804.","journal-title":"Cochrane Database Syst Rev"},{"key":"3129_CR103","doi-asserted-by":"publisher","first-page":"e2339723","DOI":"10.1001\/jamanetworkopen.2023.39723","volume":"6","author":"SC Zimmerman","year":"2023","unstructured":"Zimmerman SC, Ferguson EL, Choudhary V, Ranatunga DK, Oni-Orisan A, Hayes-Larson E, et al. Metformin Cessation and Dementia Incidence. JAMA Network Open. 2023;6:e2339723.","journal-title":"JAMA Network Open"},{"key":"3129_CR104","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.peptides.2017.11.017","volume":"100","author":"VA Gault","year":"2018","unstructured":"Gault VA, H\u00f6lscher C. GLP-1 receptor agonists show neuroprotective effects in animal models of diabetes. Peptides. 2018;100:101\u20137.","journal-title":"Peptides"},{"key":"3129_CR105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","volume":"13","author":"J Mei","year":"2024","unstructured":"Mei J, Li Y, Niu L, Liang R, Tang M, Cai Q, et al. SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Transl Neurodegener. 2024;13:41.","journal-title":"Transl Neurodegener"},{"key":"3129_CR106","unstructured":"Edison P. From the Alzheimer\u2019s association international conference 2024 glp-1 drug liraglutide may protect against dementia 2024. chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/https:\/\/aaic.alz.org\/downloads2024\/AAIC-2024-GLP-1-Ph2-trial.pdf2024."},{"key":"3129_CR107","doi-asserted-by":"publisher","first-page":"102689","DOI":"10.1016\/j.eclinm.2024.102689","volume":"73","author":"B Tang","year":"2024","unstructured":"Tang B, Sj\u00f6lander A, Wastesson JW, Maura G, Blotiere P-O, Szilcz M, et al. Comparative effectiveness of glucagon-like peptide-1 agonists, dipeptidyl peptidase-4 inhibitors, and sulfonylureas on the risk of dementia in older individuals with type 2 diabetes in Sweden: an emulated trial study. eClinicalMedicine. 2024;73:102689.","journal-title":"eClinicalMedicine"},{"key":"3129_CR108","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/13872877251319054","volume":"104","author":"EK Hui","year":"2025","unstructured":"Hui EK, Mukadam N, Kohl G, Livingston G. Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta-analysis. J Alzheimers Dis. 2025;104:627\u201348.","journal-title":"J Alzheimers Dis"},{"key":"3129_CR109","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, et al. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet. 2025;405:627\u201336.","journal-title":"Lancet"},{"key":"3129_CR110","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1212\/WNL.0000000000009781","volume":"95","author":"A Rahman","year":"2020","unstructured":"Rahman A, Schelbaum E, Hoffman K, Diaz I, Hristov H, Andrews R, et al. Sex-driven modifiers of Alzheimer risk: a multimodality brain imaging study. Neurology. 2020;95:e166\u2013e78.","journal-title":"Neurology"},{"key":"3129_CR111","first-page":"792","volume":"32","author":"HK Park","year":"2024","unstructured":"Park HK, Marston L, Mukadam N. The effects of estrogen on the risk of developing dementia: a cohort study using the UK Biobank data. Am J Geriatr Psychiatry. 2024;32:792\u2013805.","journal-title":"Am J Geriatr Psychiatry"},{"key":"3129_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.586909","volume":"11","author":"Z Cai","year":"2020","unstructured":"Cai Z, Li H. An updated review: androgens and cognitive impairment in older men. Front Endocrinol. 2020;11:586909.","journal-title":"Front Endocrinol"},{"key":"3129_CR113","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/BF02245172","volume":"107","author":"C Flicker","year":"1992","unstructured":"Flicker C, Ferris SH, Serby M. Hypersensitivity to scopolamine in the elderly. Psychopharmacology. 1992;107:437\u201341.","journal-title":"Psychopharmacology"},{"key":"3129_CR114","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamaneurol.2016.0580","volume":"73","author":"SL Risacher","year":"2016","unstructured":"Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol. 2016;73:721\u201332.","journal-title":"JAMA Neurol"},{"key":"3129_CR115","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1136\/jnnp.66.2.137","volume":"66","author":"PT Francis","year":"1999","unstructured":"Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer\u2019s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66:137\u201347.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3129_CR116","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S2666-7568(21)00150-1","volume":"2","author":"M Iwagami","year":"2021","unstructured":"Iwagami M, Qizilbash N, Gregson J, Douglas I, Johnson M, Pearce N, et al. Blood cholesterol and risk of dementia in more than 1.8 million people over two decades: a retrospective cohort study. Lancet Healthy Longev. 2021;2:e498\u2013506.","journal-title":"Lancet Healthy Longev"},{"key":"3129_CR117","doi-asserted-by":"publisher","first-page":"e019399","DOI":"10.1136\/bmjopen-2017-019399","volume":"8","author":"A Gimson","year":"2018","unstructured":"Gimson A, Schlosser M, Huntley JD, Marchant NL. Support for midlife anxiety diagnosis as an independent risk factor for dementia: a systematic review. BMJ Open. 2018;8:e019399.","journal-title":"BMJ Open"},{"key":"3129_CR118","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1176\/appi.ps.201500011","volume":"66","author":"V Bali","year":"2015","unstructured":"Bali V, Chatterjee S, Carnahan RM, Chen H, Johnson ML, Aparasu RR. Risk of dementia among elderly nursing home patients using paroxetine and other selective serotonin reuptake inhibitors. Psychiatr Serv. 2015;66:1333\u201340.","journal-title":"Psychiatr Serv"},{"key":"3129_CR119","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1136\/jnnp-2024-334675","volume":"96","author":"A Paris","year":"2025","unstructured":"Paris A, Amirthalingam G, Karania T, Foote IF, Dobson R, Noyce AJ, et al. Depression and dementia: interrogating the causality of the relationship. J Neurol Neurosurg Psychiatry. 2025;96:573\u201381.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3129_CR120","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1001\/jamapsychiatry.2014.2476","volume":"72","author":"RH Pietrzak","year":"2015","unstructured":"Pietrzak RH, Lim YY, Neumeister A, Ames D, Ellis KA, Harrington K, et al. Amyloid-\u03b2, anxiety, and cognitive decline in preclinical Alzheimer disease: a multicenter, prospective cohort study. JAMA Psychiatry. 2015;72:284\u201391.","journal-title":"JAMA Psychiatry"},{"key":"3129_CR121","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15:888\u201398.","journal-title":"Alzheimers Dement"},{"key":"3129_CR122","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/jech-2021-217090","volume":"76","author":"T Wilkinson","year":"2022","unstructured":"Wilkinson T, Schnier C, Bush K, Rannikm\u00e4e K, Lyons RA, McTaggart S, et al. Drug prescriptions and dementia incidence: a medication-wide association study of 17000 dementia cases among half a million participants. J Epidemiol Community Health. 2022;76:223\u20139.","journal-title":"J Epidemiol Community Health"},{"key":"3129_CR123","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/jech-2011-200314","volume":"66","author":"J Gallacher","year":"2012","unstructured":"Gallacher J, Elwood P, Pickering J, Bayer A, Fish M, Ben-Shlomo Y. Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). J Epidemiol Community Health. 2012;66:869\u201373.","journal-title":"J Epidemiol Community Health"},{"key":"3129_CR124","doi-asserted-by":"publisher","first-page":"402","DOI":"10.7326\/ANNALS-24-01871","volume":"178","author":"MA Hern\u00e1n","year":"2025","unstructured":"Hern\u00e1n MA, Dahabreh IJ, Dickerman BA, Swanson SA. The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med. 2025;178:402\u20137.","journal-title":"Ann Intern Med"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03129-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03129-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:03:42Z","timestamp":1760598222000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03129-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":124,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3129"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03129-3","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JFH has received consultancy fees from Wellcome Trust, Juli Inc and Swiss Re. He holds shares in juli Inc and has a patent pending. All other authors have no declarations of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}